Turning the complexity
of a solid tumor against itself
Personalized, whole tumor-derived immunotherapies
Our science
Harnessing decades of research and multiple validated technologies, Imvax’s unique platform captures a tumor’s full antigen signature and uses it to stimulate the patient’s innate immunity against remaining tumor cells
Our Pipeline
With promising clinical data in Glioblastoma and preclinical data in multiple other solid tumors, Imvax is developing a diverse pipeline of personalized, whole tumor-derived treatments